Voir cette page en français Omicron Variant Update: Click Here to read our latest update on the impact of the Omicron variant of SARS-CoV-2 on COVID-19 Antigen Rapid Test Device. The Rapid Response™ COVID-19 Antigen Rapid Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal and nasopharyngeal secretions from individuals suspected of COVID-19 within 6 days of symptom onset and from individuals without symptoms or other epidemiological reasons to suspect COVID-19 infection, when tested twice over two (or three) days with at least 24 hours (and no more than 36 hours) between tests. This test is authorized for use at the Point of Care i.e., in patient care setting. This product is available in both 5 tests per kit and 25 test per kit sizes.
